arise infusion
THERAPY SERVICES
A DIVISION OF ARTHRITIS AND RHEUMATISM ASSOCIATES, PC

Fax To: 301-424-3590
Have a Question? Call: 240-514-5000

OCREVUS (Ocrelizumab) ORDER FORM

REFERRAL TYPE

☐ New Referral ☐ Order Renewal ☐ Restart ☐ Frequency Change ☐ Dosage Change

PREFERRED LOCATION

☐ 2730 University Blvd. West | Suite 714 Wheaton, MD 20902	☐ 14995 Shady Grove Road | Suite 250 Rockville, MD 20850	☐ 5454 Wisconsin Avenue | Suite 600 Chevy Chase, MD 20815
☐ 18111 Prince Philip Drive | Suite 323 Olney, MD 20832	☐ 71 Thomas Johnson Drive Frederick, MD 21702	☐ 2021 K Street, NW | Suite 300 Washington, DC 20006
	☐ 3027 Javier Road | Suite 2 Fairfax, VA 22031	

PATIENT INFORMATION

Name:	DOB:	Email:
Address:	Weight: KG LBS	Phone:

REFERRING PHYSICIAN INFORMATION

Name:		NPI:
Office Contact Name:	Phone:	Fax:
Address:		

OCREVUS ORDER

We do not accept off-label diagnoses, dosages, or frequencies.

Dosing/Frequency:

☐ Initial Dose: 300mg IV at 0 and 2 weeks, then 600mg IV every 6 months

☐ Maintenance Dose: 600mg IV every 6 months

Diagnosis:

☐ G35—Multiple Sclerosis

Please identify the type of MS the patient has been diagnosed with:

☐Relapsing-remitting MS ☐Secondary-progressive MS ☐Primary-progressive MS ☐Progressive-relapsing MS

☐ Other Diagnosis: ICD-10 Code (Required):

Ambulate: ☐Independent ☐With Assistance ☐Wheelchair **NOTICE: ARISE cannot facilitate treatment for patients on a stretcher.**

Special Instructions:

Physicians Signature:	Date: *(Order is Valid for One Year)*

REQUIRED DOCUMENTATION

Please fax the following documents and records:

- Patient Demographics
- Two most recent office notes (Supporting the DX and treatment ordered)
- Most recent labs that include values for:
  - CMP, CBC, HBV Surface Antigen
- Most recent MRI report
- Copy of the patient's insurance card(s) – front and back
- Medication History
- For continuation of treatment, include the last infusion note
- Statement of Medical Necessity (SMN) form supplied by Genentech/AccessSolutions

We will contact the patient and schedule their treatment once our benefit investigation and any prior authorizations have been completed.